|
|
 |
Vaccine
Information Statements
VISs by language
Japanese-language VISs
Up-to-date
You
are encouraged to distribute the up-to-date English-language
VIS at the same time
as the translation.
|
|
|
Japanese-language VISs
Out-of-date
The translations for some VISs on our website are from previously
published English-language versions that have since been updated.
Unfortunately, IAC is not always able to obtain translations as
updates are issued. Please ensure that your patients receive
information consistent with the current English-language version of
the following VISs.
You are
encouraged to distribute the up-to-date English-language
VIS at the
same time as the translation.
These translations do not
contain the following CDC updates:
- Information was added about MMRV vaccine, tied to the
March 14 MMWR, regarding increased risk of certain adverse events,
including febrile seizures, with MMRV when compared with MMR and
varicella vaccines given separately. Aside from two boxes containing
information about MMRV, both VISs are identical to the previous
editions.
- The new VISs should be used when MMRV is given; but the existing
stocks of the individual MMR and varicella VISs may be used when the
vaccines are given separately.
This translation does not contain the
following CDC updates:
- Section 1: The
answer has been rewritten by CDC.
- Section 2: There
are now 2 doses; the first dose is 12-15 months and the second
dose is 4-6 years.
- CDC added information
on MMRV.
- The URL for Vaccine
Adverse Event Reporting System (VAERS) has changed to www.vaers.hhs.gov.
- The URL for the
National Vaccine Injury Compensation Programs has changed to
www.hrsa.gov/vaccincompensation.
These translations do not contain the following
CDC updates:
- These translations do not contain the following CDC updates
- The main change is in Section 4, which now mentions Tdap.
- The NVICP and VAERS web addresses have also been updated
- The mortality rate for tetanus in Section 1 changed from 1 out of
10, to 2 out of 10 cases.
- The date changed to 5/17/07.
This translation does not contain the
following CDC updates:
- CDC changed the
indication to 1 year or older and has recommended routine use
for children.
- Section 2: Added
persons who work with primates or in research labs to indications
(routine vaccination).
- Added bullet for "persons
who live in communities that have prolonged outbreaks of hepatitis
A."
- Divided the section
into "Who" and "When" parts.
- Removed southern
Europe from list of regions with high rates of hepatitis A.
- Section 3: Added
bullet about allergy to vaccine component.
- Changed wording,
particularly the statement on pregnancy, and made list into
bullets.
- Minor changes to
part 4, 5, and 6 to be consistent with other recent VISs.
- Removed the section
on immune globulin.
These translations do not contain the
following CDC updates:
- On July 18, the CDC posted an interim
VIS for hepatitis B. There are minor changes throughout, but the main
purpose of the update is to emphasize the birth dose for all children.
- A final version will be developed.
This translation does not contain the
following CDC updates:
- CDC added recommending
vaccination of children aged 24-59 months and their contacts.
- Section
3: CDC added to the list of people at high risk for complications
from influenza, "People with certain muscle or nerve disorders
(such as seizure disorders or severe cerebral palsy) that can
lead to breathing or swallowing disorders."
This translation does not contain the
following CDC updates:
- CDC added recommending
vaccination of children aged 24-59 months and their contacts.
These translations do not contain the following
CDC updates:
- The CDC posted an updated interim PCV VIS on 12/9/08. The main
reason is to incorporate recent changes in recommendations for 2-4 year
olds, but there are other changes throughout as well. There are no
changes in contraindications or adverse events, but to prevent parents
from getting confused about the differences in indications (especially
when the vaccine is administered to 2-4 year olds) it would be best for
providers to start using the new version right away. Existing stocks CAN
still be used temporarily if immediately switching to the new version is
a problem.
Thanks to
the California Department of Health Services for their translations.
This page was updated on December 11, 2008 |
|
|
|
|
|
|
|
| Immunization Action Coalition 1573 Selby Avenue Saint Paul, MN 55104 |
|
| tel 651-647-9009 fax 651-647-9131 |
|
| email admin@immunize.org |
|